BR0114762A - Composições farmacêuticas contendo ácidos oxapenem-3-carboxìlicos - Google Patents

Composições farmacêuticas contendo ácidos oxapenem-3-carboxìlicos

Info

Publication number
BR0114762A
BR0114762A BR0114762-5A BR0114762A BR0114762A BR 0114762 A BR0114762 A BR 0114762A BR 0114762 A BR0114762 A BR 0114762A BR 0114762 A BR0114762 A BR 0114762A
Authority
BR
Brazil
Prior art keywords
oxapenem
pharmaceutical compositions
carboxylic acids
compositions containing
zwiterion
Prior art date
Application number
BR0114762-5A
Other languages
English (en)
Inventor
Hans Rudolf Pfaendler
Iain Nelson Simpson
Original Assignee
Amura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00309207A external-priority patent/EP1199077A1/en
Priority claimed from GB0105766A external-priority patent/GB0105766D0/en
Priority claimed from GB0119165A external-priority patent/GB2369358A/en
Application filed by Amura Ltd filed Critical Amura Ltd
Publication of BR0114762A publication Critical patent/BR0114762A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS CONTENDO áCIDOS OXAPENEM-3-CARBOXìLICOS". Um composto de oxapenema o qual é, ou é capaz de formar, um zwiteríon de fórmula Ia ou Ib: (Ia), (Ib) onde R é um grupo alquila de cadeia ramificada ou reta C~ 1~-C~ 8~ o qual inclui um substituinte básico protonado. Os compostos encontram uso particular como inibidores de <225>-lactamase de alta biodisponibilidade.
BR0114762-5A 2000-10-19 2001-10-11 Composições farmacêuticas contendo ácidos oxapenem-3-carboxìlicos BR0114762A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00309207A EP1199077A1 (en) 2000-10-19 2000-10-19 Stable compositions of oxapenem-3-carboxylic acids by Co-lyophilisation with pharmaceutical carriers
GB0105766A GB0105766D0 (en) 2001-03-08 2001-03-08 Orally active compounds
GB0119165A GB2369358A (en) 2000-10-19 2001-08-06 Oxapenems and pharmaceutical compositions thereof
PCT/GB2001/004527 WO2002032423A1 (en) 2000-10-19 2001-10-11 Pharmaceutical compositions containing oxapenem-3-carboxylic acids

Publications (1)

Publication Number Publication Date
BR0114762A true BR0114762A (pt) 2003-10-07

Family

ID=27223564

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114762-5A BR0114762A (pt) 2000-10-19 2001-10-11 Composições farmacêuticas contendo ácidos oxapenem-3-carboxìlicos

Country Status (18)

Country Link
US (1) US7247622B2 (pt)
EP (1) EP1326607B1 (pt)
JP (1) JP4283535B2 (pt)
CN (1) CN1219512C (pt)
AT (1) ATE401884T1 (pt)
AU (2) AU9400401A (pt)
BR (1) BR0114762A (pt)
CA (1) CA2425314C (pt)
CZ (1) CZ296089B6 (pt)
DE (1) DE60135002D1 (pt)
DK (1) DK1326607T3 (pt)
ES (1) ES2310561T3 (pt)
HK (1) HK1053793A1 (pt)
HU (1) HUP0500956A3 (pt)
IL (1) IL155183A0 (pt)
MX (1) MXPA03003280A (pt)
PL (1) PL206257B1 (pt)
WO (1) WO2002032423A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0106428D0 (en) * 2001-03-15 2001-05-02 Amura Ltd Antibacterial composition
WO2011049919A1 (en) 2009-10-23 2011-04-28 Dow Corning Corporation Hydrophilically-modified silicone compositions
CA2851984C (en) * 2011-10-14 2020-10-27 Universite De Liege Method for measuring beta-lactam antibiotics

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2045236A (en) 1979-03-26 1980-10-29 Hoechst Uk Ltd Oxapenem derivatives
US4293555A (en) * 1979-04-17 1981-10-06 Merck & Co., Inc. 6- and 6,6-Disubstituted-2-substituted-oxapen-2-em-3-carboxylic acids
DE3725375A1 (de) 1987-07-31 1989-02-09 Bayer Ag Stabile oxapenem-3-carbonsaeuren
DE3833693A1 (de) * 1988-10-04 1990-04-05 Bayer Ag Stabile oxapenem-3-carbonsaeuren und ihre verwendung als ss-lactamasehemmer
DE4027928A1 (de) 1990-09-04 1992-03-05 Bayer Ag Neue 2-tert.substituierte methyl-oxapenem-3-carbonsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung
DE4142423A1 (de) 1991-12-20 1993-06-24 Pfaendler Hans Rudolf ((ls)-hydroxyalkyl)oxapenem-3-carbonsaeuren und ihre verwendung als betalactamasehemmer
WO1996038450A1 (en) 1995-05-31 1996-12-05 Microcide Pharmaceuticals, Inc. Cephalosporin antibiotics
EP1199077A1 (en) * 2000-10-19 2002-04-24 Amura Limited Stable compositions of oxapenem-3-carboxylic acids by Co-lyophilisation with pharmaceutical carriers
GB0106428D0 (en) * 2001-03-15 2001-05-02 Amura Ltd Antibacterial composition

Also Published As

Publication number Publication date
PL206257B1 (pl) 2010-07-30
CA2425314A1 (en) 2002-04-25
ATE401884T1 (de) 2008-08-15
EP1326607B1 (en) 2008-07-23
US20040067929A1 (en) 2004-04-08
IL155183A0 (en) 2003-11-23
AU9400401A (en) 2002-04-29
JP2004511519A (ja) 2004-04-15
US7247622B2 (en) 2007-07-24
CN1219512C (zh) 2005-09-21
HUP0500956A3 (en) 2013-01-28
HK1053793A1 (en) 2003-11-07
PL361312A1 (en) 2004-10-04
DK1326607T3 (da) 2008-11-17
CA2425314C (en) 2009-04-28
WO2002032423A1 (en) 2002-04-25
CZ20031214A3 (cs) 2003-10-15
MXPA03003280A (es) 2004-12-13
EP1326607A1 (en) 2003-07-16
HUP0500956A2 (en) 2006-05-29
ES2310561T3 (es) 2009-01-16
DE60135002D1 (de) 2008-09-04
AU2001294004B2 (en) 2007-04-26
CZ296089B6 (cs) 2006-01-11
CN1469744A (zh) 2004-01-21
JP4283535B2 (ja) 2009-06-24

Similar Documents

Publication Publication Date Title
BR0014133A (pt) Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
BR0014136A (pt) Composto, uso do mesmo, métodos para a preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR0012434A (pt) Composto, processo para a preparação do mesmo, uso de um composto, composição farmacêutica.
BR0206738A (pt) Derivados tricìclicos de lactama e de sultama e uso dos mesmos como inibidores de histona desacetilase
BR0112068A (pt) Compostos orgânicos
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
BR0206943A (pt) Inibidores de fosfodiesterase 4
EA200200628A1 (ru) Новые производные 1,3-дигидро-2н-индол-2-она и их применение в качестве лигандов рецепторов аргинин-вазопрессина v1b и v1a
RS51401B (en) TIENO [3,2-D] PIRIMIDINSKI DERIVAT KOJI JE KORISTAN KAO INHIBITOR P13K
BR0115580A (pt) Derivados de 3-aroilindol e a utilizaçao dos mesmos como agonistas dos receptores cb2
EA200200942A1 (ru) Фармацевтические композиции, содержащие производные 3-аминоазетидина, новые производные и способ их получения
SE9203825D0 (sv) Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
EA200200912A1 (ru) Новые производные индолин-2-она, их получение и их применение в качестве лигандов рецепторов окситоцина
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BRPI0510397A (pt) compostos, composições farmacêuticas contendo os mesmos, e métodos de uso dos mesmos
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
BR0100234A (pt) Compostos de piperidina-4-sulfonamida, processo para a sua preparação e composições farmacêuticas contendo os mesmos
ATE236176T1 (de) Neue substrate zur detektion von mikrobiellen metaboliten
MA29482B1 (fr) Derives de benzothiazol-2-one derivatives en tant qu&#39;inhibiteurs de lipase et de phospholipase
BR0109022A (pt) Método de preparação de citalopram e sua composição farmacêutica
ATE550332T1 (de) 4-imidazolin-2-onverbindungen als p38-map- kinaseinhibitors

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]